Compare DexCom, Inc. (DXCM) vs Figs Inc (FIGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Figs Inc — how do they compare? DexCom, Inc. trades at $77.98 (market cap $28.06B), while Figs Inc trades at $9.93 (market cap $1.66B). The key difference: DexCom, Inc. is far larger — about 16.9× Figs Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Figs Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | FIGS | |
|---|---|---|
Market Cap | $28.06B | $1.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $17.12 |
52-Week Low | $54.84 | $5.81 |
Enterprise Value | $27.03B | $1.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
FIGS trades at $10.08, up 3.7% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $631.1M in 2025 (Zacks Investment Research, 2026-05-07), but net cash flow remains negative. Analyst consensus is Buy with a $19.50 target, though technical indicators show selling pressure.
Outlook hinges on global expansion and margin management amid cost pressures. Risks include competitive threats and volatile cash flows, but strong customer growth and premium positioning offer upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
